Local Drug Delivery for Coronary Artery Disease: Established and Emerging Applications

by Camenzind; Edoardo

• ISBN13: 9781841840451
• ISBN10: 1841840459
• eBook ISBN(s): 9781135417987
• Format: Hardcover
• Copyright: 2005-06-14
• Publisher: CRC Press
• More Book Details

Summary

"Local Drug Delivery for Coronary Artery Disease is a comprehensive and up-to-date overview on site-specific therapy for the treatment of arterial disease. The first section of the book deals with both the purpose of site specific treatment - reaching from arterial-wall passivation to restenosis prevention - and also the physico-chemical challenge linked to this treatment modality. A summary of the performed experimental and clinical work using the different catheter- and stent-platforms as well as the different molecular approaches is provided in the syllabus section. In the third section, each chapter represents an in-depth description and elaboration of the different issues summarized in the syllabus. Lastly a critical overview of the drug eluting stents is given to allow the reader to develop a critical and knowledgeable opinion on the impressive clinical results obtained with these new technologies. Local Drug Delivery for Coronary Artery Disease will be a source of information for both physicians and medical students."--BOOK JACKET.

Table of Contents

The purpose of site-specific therapy	p. 1
Local drug delivery : impact of pressure, substance characteristics, and stenting on drug transfer into the arterial wall	p. 7
Catheter-based and stent-based treatment for coronary artery disease	p. 11
The ClearWay microporous balloon catheter	p. 41
The dispatch coronary infusion catheter	p. 47
The remedy PTCA dilatation infusion catheter	p. 53
The infiltrator angioplasty balloon catheter	p. 59
The infiltrator local drug delivery catheter	p. 63
The needle catheter	p. 67
Stent-mediated local drug delivery	p. 79
Silicon carbide-coated stents	p. 99
Carbostent : a carbofilm - coated stent	p. 107
The PC-coated BiodivYsio stent	p. 115
PTFE-covered stents	p. 121
Overview of drug delivery coatings	p. 127
Phosphorylcholine (PC Technology) coated stents as a drug delivery platform	p. 139
Direct stent coating : an alternative for polymers?	p. 151
Radioactive stents	p. 163
Overview of potential drugs to inhibit in-stent restenosis	p. 171
Direct antithrombins	p. 173
Tissue factor inhibitors	p. 177
Nitric oxide-related interventions and restenosis	p. 181
Vitamin E and its multiple properties : anti, pro, and non-oxidative activities	p. 197
The dexamethasone eluting stent	p. 209
Anti-inflammatory approaches to restenosis	p. 215
The role of matrix metalloproteinase inhibitors after arterial injury	p. 229
Methotrexate : a potential drug for stent-mediated local drug delivery : anti-inflammatory and antiproliferative characteristics	p. 239
Actin-skeleton inhibitors : potential candidates for local drug delivery in the prevention of in-stent restenosis?	p. 249
Local delivery of antisense to c-myc for the prevention of restenosis	p. 265
Site-specific delivery of cytostatic agents	p. 275
Catheter-based delivery of NOS gene	p. 281
Carbon-coated stents : diamond-like stent coatings	p. 289
Long-term biocompatibility evaluation of poly-bis-trifluorethoxyphosphazene (PTFEP) : a novel biodegradable polymer stent coating in a porcine coronary stent model	p. 297
Biocompatibility evaluation of biosoluble stent coatings in a porcine coronary stent model	p. 307
Glycoprotein (GP) GIIb/IIIa receptor antagonist eluting stents	p. 311
Activated protein C eluting stents	p. 315
Local methylprednisolone delivery using a BiodivYsio phosphorylcholine (PC)-coated drug delivery stents reduces inflammation and neointimal hyperplasia in a porcine coronary stent model	p. 317
Methotrexate loaded BOBSC-coated coronary stents reduce neointimal hyperplasia in a porcine coronary model	p. 325
Rapamycin eluting stents	p. 337
Preclinical evaluation of tacrolimus-coated coronary stents	p. 343
Local delivery of paclitaxel as a stent coating	p. 355
Addition of cytochalasin D to a biodegradable oil stent coating inhibits intimal hyperplasia in a porcine coronary model	p. 363
Vascular endothelial growth factor (VEGF) eluting stents	p. 377
An advanced antisense for local and stent based delivery for prevention of restenosis	p. 381
Stent-based gene delivery	p. 393
Catheter-based local heparin delivery	p. 397
Local delivery of low molecular weight heparins	p. 405
Local delivery of steroids before coronary stent implantation	p. 411
Clinical studies with the carbostent	p. 427
Gold-coated stents	p. 433
Heparin-coated stent trials	p. 435
The blue medical 50% TEMPO coronary stent : preclinical studies and the first clinical pilot trial	p. 443
Dexamethasone : mode of action, preclinical, and clinical studies	p. 457
17[beta]-estradiol-eluting stents : a potential therapy in the prevention of restenosis	p. 471
Batimastat : mode of action, preclinical, and clinical studies	p. 483
The FIM trial : sirulimus eluting stents	p. 499
Tacrolimus eluting stents	p. 503
Everolimus eluting stents	p. 507
The quantum drug eluting stent and the SCORE trial	p. 515
The Boston scientific paclitaxel eluting stent : TAXUS I and II	p. 523
Clinical results with non-polymer based taxol eluting stents. The European evaLUation of pacliTaxel eluting stent (ELUTES) trial	p. 535
Intrapericardial drug delivery for prevention of restenosis	p. 549
Alternatives to drug eluting stents : safety and efficacy of systemic delivery of antiproliferative therapy to reduce in-stent neointimal hyperplasia	p. 559
Drug eluting stents : a critical perspective	p. 573
Table of Contents provided by Blackwell. All Rights Reserved.